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and T cells to synthesize the cytokines FLT3L, CSF-2, and TNF. These cytokines redundantly caused
DC expansion and activation, which resulted in improved antigen processing and correlated with favor-
able anticancer responses in mice and patients. Thus, IL-2 immunotherapy-mediated stimulation of DCs
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Tumor-infiltrating dendritic cells (DCs) correlate with effective anti-cancer immunity and 
improved responsiveness to anti-PD-1 checkpoint immunotherapy. However, the drivers 
of DC expansion and intratumoral accumulation are ill-defined. We found that interleukin-
2 (IL-2) stimulated DC formation through innate and adaptive lymphoid cells in mice and 
humans, and this increase in DCs improved anti-cancer immunity. Administration of IL-2 
to humans within a clinical trial and of IL-2 receptor (IL-2R)-biased IL-2 to mice resulted 
in pronounced expansion of type-1 DCs, including migratory and cross-presenting subsets, 
and type-2 DCs, although neither their precursors nor mature DCs had functional IL-2Rs. 
In mechanistic studies, IL-2 signals stimulated innate lymphoid cells, natural killer cells, 
and T cells to synthesize the cytokines FLT3L, CSF-2, and TNF. These cytokines 
redundantly caused DC expansion and activation, which resulted in improved antigen 
processing and correlated with favorable anti-cancer responses in mice and patients. Thus, 
IL-2 immunotherapy-mediated stimulation of DCs contributes to anti-cancer immunity by 
rendering tumors more immunogenic. 
 
ONE SENTENCE SUMMARY 
IL-2 immunotherapy expands tumor-infiltrating DCs through a lymphoid pathway, 
favoring the conversion of poorly immunogenic into immunogenic tumors.
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INTRODUCTION 
Dendritic cells (DCs) are a subgroup of professional antigen-presenting cells considered 
indispensable in orchestrating T cell responses to intracellular pathogens and tumors (1-3). 
Human blood DCs have traditionally been subdivided into conventional DCs (cDC) and 
plasmacytoid DCs (pDC); however, results from single-cell RNA and protein analysis 
identified additional subpopulations (4, 5). In mouse lymphoid organs, DCs are 
correspondingly divided into cDCs and pDCs. Transcriptionally, cDCs can be further 
differentiated into type-1 cDCs (cDC1) that are controlled by interferon-regulatory factor 
8 (IRF8) and basic leucine zipper transcriptional factor ATF-like 3 (BATF3) and type-2 
cDCs (cDC2) that are controlled by IRF4 (2, 3). The transcription factor E2-2 regulates 
pDCs (3). Phenotypically, cDC1s are characterized by the presence of CD141 (also known 
as BDCA-3) and DNGR-1 (also termed CLEC9A) in humans and CD8a, CD103 (also 
known as integrin aE), DNGR-1, and the chemokine receptor XCR1 in mice. Conversely, 
cDC2s are marked by CD1c (also referred to as BDCA-1) in humans and CD4 and CD11b 
in mice (6). 
 DC subsets in non-lymphoid tissues, including the tumor microenvironment 
(TME), vary considerably in terms of phenotypic and functional properties (7). In cancer, 
rare tumor-infiltrating cDCs attract T cells to the TME, where the cDCs stimulate CD8+ T 
cells by presenting tumor antigens and producing interleukin-12 (IL-12) (8-14). However, 
the upstream molecular and cellular factors favoring the on-demand generation and 
expansion of cDCs in anti-tumor responses are ill-defined. Two studies have implicated 
natural killer (NK) cells in facilitating DC infiltration of tumors, which correlated with 
prolonged survival in humans (15, 16). 
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 NK cells are lymphoid cells, and their survival and homeostasis depends on signals 
mediated through the common gamma chain cytokine receptor (γc, also termed CD132), 
encoded by Il2rg. Members of the CD132 cytokine family comprise IL-2, IL-4, IL-7, IL-
9, IL-15, and IL-21 (17, 18). IL-2 signals either through an intermediate-affinity dimeric 
IL-2 receptor (IL-2R), comprised of IL-2Rβ (CD122) and CD132, or a trimeric IL-2R 
additionally including IL-2Ra (CD25). The dimeric receptor is found mainly on memory 
CD8+ T and NK cells, whereas the trimeric receptor is predominantly found on regulatory 
T (Treg) cells at the steady state and is transiently upregulated on recently activated effector 
T cells (17, 19). In addition to its effects on T cells and NK cells, IL-2 can also stimulate 
innate lymphoid cells (ILC), particularly type 2 ILCs (ILC2), NKT cells, and activated B 
cells, as well as certain non-immune cells (19-21). However, IL-2 is not known to affect 
DC homeostasis in vivo. 
 Thus, it was entirely unexpected to observe a prominent increase in several DC 
subsets in both mice and humans during our studies on IL-2 immunotherapy. We here 
describe a pathway driven by IL-2 and mediated by innate and adaptive lymphoid cells. 
This pathway stimulates DCs and promotes their expansion, processes that contribute to 




IL-2 immunotherapy expands cDCs in mice and humans 
DCs are characterized by the absence of lineage (Lin) markers, have intermediate (int) or 
high (hi) CD11c, and can further be subdivided into CD11cint B220hi pDCs, CD11chi major 
histocompatibility class II (MHC-II)hi cDCs, CD11blow XCR1+ CD8a+ DNGR-1 
(CLEC9A)+ cDC1s, and CD11bhi XCR1– cDC2s (Fig. 1A and fig. S1A). A short course of 
three injections of recombinant human IL-2 (IL-2; teceleukin) increased total counts of 
cDCs in spleens of adult wild-type mice (Fig. 1B). This expansion was due to active 
proliferation of cDCs, as evidenced by increased incorporation of the thymidine analog 
bromodeoxyuridine (BrdU) into cDCs (Fig. 1C). To assess whether this IL-2 effect was 
caused by binding of IL-2 to CD25hi or CD122hi cells, we used CD25-biased IL-2/anti-IL-
2 (5344) antibody complexes (IL-2/5344) and CD122-biased IL-2/anti-IL-2 (NARA1) 
antibody complexes (IL-2/NARA1; referred to as IL-2cx exclusively hereafter) (22-24). 
Both CD25-biased and CD122-biased IL-2/anti-IL-2 antibody complexes stimulated 
qualitatively and quantitatively comparable expansion and proliferation of splenic DCs as 
unbiased IL-2 (Fig. 1B, C; fig. S1B, C), whereas treatment of Il2rg–/–Rag2–/– mice with IL-
2cx did not expand DCs (fig. S1D), thus excluding non-IL-2–mediated stimulation by 
interactions of anti-IL-2-antibody with Fc receptors on DCs. Moreover, IL-2cx not only 
mediated expansion of splenic cDCs, but also increased total cDC, cDC1, and cDC2 counts 
in mouse lymph nodes (fig. S1E). 
 A detailed analysis of DC subsets showed that administration of IL-2cx expanded 
counts of all lymphoid-resident cDC subsets, including CD11blow XCR1+ cDC1s and 
CD11bhi XCR1– cDC2s, whereas pDCs remained unchanged compared to untreated mice 
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(Fig. 1D and fig. S1F). These increased cell counts were accompanied by proliferation of 
all cDC subsets and pDCs, as evidenced by BrdU positivity (Fig. 1E and fig. S1G). 
 We also analyzed human CD11c+ MHC-II (HLA-DR)+ DCs within an investigator-
initiated clinical trial (termed Charact-IL-2; NCT 03312335) using recombinant human IL-
2 (aldesleukin) immunotherapy (Fig. 1F). We observed an increase in the proliferation of 
CD141+ cDC1s and CD1c+ cDC2s (Fig. 1G). Different clinical trials testing aldesleukin 
reported the expected proliferation of CD4+ and CD8+ T cells and NK cells upon 
aldesleukin immunotherapy (25, 26). However, by comparing Ki67+ DCs on day 0 (before) 
and day 5 (that is 1 day after the last injection) of a 5-day course of daily aldesleukin, we 
found an increase of proliferating cDC1s and cDC2s (Fig. 1G). 
 Mature cDCs, identified as CD11chi MHC-IIhi cells that are negative for colony-
stimulating factor 1 receptor (CSFR1, also termed CD115), were purified from spleens of 
control versus IL-2cx–treated mice and submitted to RNA sequencing (RNA-seq). Gene 
ontology (GO) analysis of the transcriptome of mature cDCs showed overrepresentation of 
genes associated with cell proliferation and activation of the immune system, including the 
GO terms cell cycle, cell division, DNA replication, chromosome segregation, nucleosome 
assembly, protein localization to kinetochore, DNA recombination, chromosome 
condensation, kinetochore organization, and microtubule depolymerization (Fig. 1H). 
Other terms, such as response to virus, response to interferon-beta, and response to 
interferon-alpha, indicated cDCs were exposed to an inflammatory environment (Fig. 1H 
and fig. S1H). Analyzing the top 75 up- and 75 downregulated genes in more detail, we 
found the genes in cDCs from the IL-2cx–treated mice were enriched in GO term genes 
associated with the complement system (Cfb, C3, C1qc, and C4b), cytotoxicity (Gzmb and 
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Gzma), and the integrin Itgae, which encodes CD103 and is associated with migratory 
cross-presenting DCs (Fig. 1I). Contrarily, Cd207, which encodes Langerin, and certain 
chemokine receptors and ligands (Ccl22, Cxcl12, and Ccr2) were downregulated. 
Interestingly, CCL22 was suggested as important in DCs for interaction with CCR4+ 
regulatory T (Treg) cells, thus implicating CCL22 in the control of excessive T cell 
responses (27). 
 Taken together, these results established pronounced stimulation of mouse and 
human cDCs following IL-2 immunotherapy in vivo. This stimulation of DCs resulted in 
proliferation of both cDC1s and cDC2s. 
 
IL-2 causes proliferation of mature cDCs and differentiation of DC precursors 
The observed proliferation and expansion of cDCs could be mediated by proliferation of 
mature cDCs or differentiation of hematopoietic DC precursors or both. To address this 
issue, we conducted a cell cycle analysis of mature splenic cDCs using propidium iodide 
staining. In line with published results stating 5% of lymphoid-resident cDCs are cycling 
(28), we detected 3.2% and 1.9% of splenic cDCs in S and G2/M phase, respectively (Fig. 
2A). Proliferating cDCs from mice treated with IL-2cx increased to 10.1% in S and 6% in 
G2/M phase (Fig. 2A). 
 To evaluate cDC differentiation from bone marrow precursors, we hierarchically 
assessed the differentiation steps of DCs, starting from monocyte/DC progenitors (MDP), 
followed by common DC progenitors (CDP) and the clonogenic progenitors precursor 
(pre)-cDC1 and pre-cDC2 (Fig. 2B) (2, 6, 29-33). IL-2 immunotherapy in mice resulted in 
a decrease of MDP, CDP, and pre-cDC2 cells in the bone marrow (Fig. 2C), with 
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simultaneous increase of splenic cDC1 and cDC2 (Fig. 2D). Bone marrow pre-cDC1 cells 
did not change, possibly due to compensatory proliferation (Fig. 2C). Because CD135 is 
used to identify DC precursors, the observed decrease in bone marrow counts could be 
partly impacted by downregulation of CD135 upon engagement with its ligand FLT3L. 
Investigating the possibility that IL-2 treatment impacts survival of cDCs, we 
measured intracellular caspase 3, which induces apoptosis downstream of the intrinsic 
pathway regulated by the B cell leukemia 2 (BCL-2) protein family and the extrinsic 
pathway mediated by death receptors activated at the cell surface (34). However, we did 
not observe any significant difference in caspase 3-positive splenic cDCs between 
untreated and IL-2cx–treated mice (Fig. 2E; P = 0.6794). Staining for live cells versus dead 
cells with Annexin-V and 7-AAD confirmed these results (fig. S2A). Additionally, in the 
intrinsic apoptosis pathway, neither the amount of BCL-2, which is the inhibitor of the pro-
apoptotic BCL-2-associated X (BAX) protein (35), nor the amount of BAX was different 
between cDCs from untreated and IL-2cx–treated mice (fig. S2, B and C). These results 
suggested no survival benefit after IL-2 treatment, yet they were measured indirectly by 
apoptosis-regulating proteins. Direct measurement of survival by adoptive transfer of cDCs 
from untreated and IL-2cx–treated mice into untreated recipients revealed a small, but 
significant, survival advantage of the IL-2cx–treated cDCs (Fig. 2F, P = 0.0015). Due to 
the increased differentiation of DC progenitors this effect could be attributed to the 
inclusion of 'younger' cDC subsets in the transferred cDCs from IL-2cx–treated mice. To 
exclude this possibility, we reversed the experimental setup and transferred cDCs from 
untreated mice to either untreated or IL-2cx–pretreated mice, observing a small, but 
insignificant increase in the IL-2cx–pretreated mice (Fig. 2G; P = 0.3148). 
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 Together, these results suggested that IL-2 treatment facilitates proliferation of 
mature cDCs and accelerated differentiation of DC progenitors to mature DCs. To a lesser 
extent, IL-2 treatment might enhance DC survival. 
 
Mature DCs and their precursors lack functional IL-2Rs 
Given the profound stimulatory effects of IL-2 on cDCs, we investigated IL-2R abundance 
on cDCs and their precursors at the mRNA and protein levels. Quantitative polymerase 
chain reaction (qPCR) of Il2r transcripts from untreated and IL-2cx–treated cDCs, CD4+ 
Foxp3– conventional T (Tcon) and CD4+ Foxp3+ Treg cells revealed that cDCs contained 
Il2rg mRNA, but they lacked Il2ra or Il2rb mRNA (Fig. 3A). In comparison, Tcon and 
Treg cells expressed mRNA for all three IL-2R subunits (Fig. 3A). We also confirmed 
these results at the protein level by surface staining for IL-2R subunits on mature mouse 
cDCs and Treg cells in untreated and IL-2cx–treated mice (Fig. 3B). As previously 
published (36, 37), cDCs upregulated CD25, but not CD122, upon stimulation with two 
different Toll-like receptor ligands (fig. S3A). We investigated IL-2R abundance on DC 
precursors. MDP and CDP lacked detectable amounts of CD132; pre-cDC1 had a slightly 
detectable amount of CD132 and pre-cDC2 had clearly detectable CD132 (Fig. 3C). MDP, 
CDP, pre-cDC1, and pre-cDC2 all lacked detectable surface CD122 and CD25, even 
following IL-2cx treatment (Fig. 3C and fig. S3B). 
 To directly assess whether mature cDCs had functional IL-2Rs, we analyzed 
downstream intracellular signaling by signal transducer and activator of transcription 5 
(STAT5), which becomes phosphorylated (pSTAT5) upon activation of a functional IL-2R 
by IL-2. As a positive control for STAT5 signaling, we also tested the cDCs response to 
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colony-stimulating factor 2 (CSF2; also termed granulocyte-macrophage colony-
stimulating factor), which also activates STAT5. Confirming the lack of functional IL-2Rs, 
even the highest concentrations of IL-2 tested failed to induce pSTAT5 in cDCs, whereas 
Treg cells readily responded to the same range of IL-2 concentrations in a dose-dependent 
manner (Fig. 3D). Conversely, pSTAT5 increased in cDCs incubated with mouse CSF2, 
whereas Treg cells remained unaffected by this stimulation (Fig. 3D). The same results 
applied to cDCs from IL-2cx–treated mice (fig. S3C). Furthermore, Lin– CD135+ DC 
precursors, including MDPs, CDPs, pre-cDC1s, and pre-cDC2s, from untreated and IL-
2cx–treated mice did not show increased pSTAT5 upon stimulation with a high dose (1,000 
IU) of IL-2, whereas incubation with mouse CSF2 increased pSTAT5 (fig. S3D). Thus, 
DC precursors do not have functional IL-2Rs. 
 Similar to their mouse counterparts, human cDCs were positive for CD132 but 
lacked detectable CD25 and CD122 at the cell surface, unlike CD4+ T cells that served as 
controls (Fig. 3E). Accordingly, stimulation of human cDCs with a high IL-2 concentration 
did not increase pSTAT5, whereas the same treatment induced pSTAT5 in human CD4+ T 
cells, and human CSF2 increased pSTAT5 in human cDCs (Fig. 3F). 
 Supporting these findings, IL-2cx treatment of bone marrow chimeric mice 
carrying a 1:1-mix of CD45.1-congenic wild-type and CD45.2-congenic Il2rg–/– DCs 
resulted in equal expansion of both wild-type and Il2rg–/– cDCs (Fig. 3G). Collectively, 
these data support a model whereby IL-2 immunotherapy indirectly activates cDCs and 
their precursors through the induction of intermediary factors. 
 
IL-2 immunotherapy causes production of several DC mitogens 
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Searching for candidates that stimulate cDCs and their precursors, we decided to assess 
FMS-like tyrosine kinase 3 ligand (FLT3L) and CSF2, because these cytokines contribute 
to the development and survival of DCs during steady state and inflammation, respectively 
(38). Untreated Flt3l–/– mice had reduced cDC counts compared to wild-type mice, 
amounting to ~1 × 106 per spleen in wild-type (Fig. 1B) versus ~2.5 × 104 per spleen in 
Flt3l–/– (Fig. 4A), thus confirming the importance of FLT3L for cDC homeostasis. 
However, similar to wild-type mice (Fig. 1B), IL-2 treatment caused a 4-fold expansion of 
cDCs in Flt3l–/– animals (Fig. 4A). Likewise, use of IL-2cx in Csf2–/– mice, which 
contained reduced steady-state numbers of cDCs compared to those in wild-type, resulted 
in an increase of splenic cDC counts (Fig. 4B). We predicted that FLT3L and CSF2 
compensated for the absence of each other, but surprisingly, Flt3l–/– Csf2–/– double-
knockout mice also showed expansion and proliferation of cDCs and corresponding subsets 
upon IL-2 treatment (Fig. 4, C and D, and fig. S4A). 
 In previous experiments, we observed that IL-2cx treatment increased tumor 
necrosis factor (TNF) in a T cell-dependent manner (39). We thus hypothesized that TNF 
stimulates cDC expansion in Flt3l–/– Csf2–/– mice. Indeed, blocking TNF with the soluble 
TNF receptor 2-Fc-IgG1 fusion protein etanercept reduced cDC expansion to close to 
background amounts in IL-2cx–treated animals (Fig. 4E). Etanercept treatment of wild-
type mice also reduced expansion and proliferation of cDCs, suggesting a FLT3L– and 
CSF2–independent effect of TNF on DC homeostasis (Fig. 4F and fig. S4B). Moreover, 
IL-2cx treatment of bone marrow chimeric mice containing a 1:1-mix of wild-type and 
Tnfrsf1a/b–/– bone marrow reduced expansion of Tnfrsf1a/b–/– cDCs, thus indicating a 
direct effect of TNF on cDCs (Fig. 4G). 
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Measurement of serum cytokines in mice showed marked increase in FLT3L and 
TNF upon IL-2 immunotherapy, whereas CSF2 was not detectable (Fig. 4H). The latter 
might be due to local action of CSF2 rather than systemic secretion (38). We found similar 
results for these cytokines in human serum before and after aldesleukin treatment (Fig. 4I). 
In summary, these results indicated that IL-2 mediates cDC expansion through secretion of 
the cytokines FLT3L, CSF2 and TNF, all of which directly stimulate cDCs (referred to 
hereafter as DC-active cytokines). 
 
IL-2–stimulated innate and adaptive lymphoid cells produce DC-active cytokines 
Our results indicated that cDCs were expanded by cytokines secreted by IL-2–responsive 
cells. Because both hematopoietic cells and non-hematopoietic cells have IL-2Rs (23), we 
investigated whether cDC-stimulating cells are of hematopoietic origin. To this end, we 
generated bone marrow chimeric mice in which wild-type or Il2rg–/– recipients were 
lethally irradiated (950 RAD) and reconstituted with wild-type or Il2rg–/– bone marrow 
(Fig. 5A, left). Only mice reconstituted with wild-type bone marrow, but those not with 
Il2rg–/– bone marrow, showed expansion of splenic cDCs after IL-2 immunotherapy, 
indicating that IL-2–responsive cells are of hematopoietic origin (Fig. 5A). 
 To evaluate potential target cells, we searched the ImmGen database (40) to identify 
mouse immune cells with functional IL-2Rs, comprising at least those with both CD122 
and CD132. By examining Il2ra, Ilr2b, and Il2rg expression, our search revealed that, in 
addition to T, NK, and NKT cells, ILCs had detectable amounts of each of these transcripts 
(fig. S5A). As previously published (22-24, 39, 41, 42), we confirmed in vivo expansion 
and proliferation of CD4+ T, CD8+ T, and NK cells upon IL-2cx treatment (fig. S5, B to 
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D). Furthermore, all ILC subsets, including type-1 ILCs (ILC1), type-2 (ILC2), and type-
3 (ILC3), showed proliferation and expansion upon IL-2 immunotherapy (Fig. 5B and fig. 
S5E). 
 To assess the contribution of each IL-2–responsive cell subset to cDC homeostasis 
and IL-2–mediated cDC expansion, we used different knockout and antibody-depletion 
strategies. Although Tcrbd–/– mice, lacking both ab and gd T cells, showed reduced counts 
of splenic cDCs compared to wild-type, amounting to ~1 × 106 per spleen in wild-type 
(Fig. 1B) versus ~3 × 105 per spleen in Tcrbd–/– (Fig. 5C), IL-2cx treatment stimulated 
expansion of cDCs in the Tcrbd–/– animals (Fig. 5C). We used Rag1–/– mice, lacking T and 
B cells, and depleted the mice of NK cells, ILCs, or both by injection of anti-NK1.1 or anti-
Thy1.2 antibodies or both antibodies. Both cell types contributed to IL-2–mediated cDC 
expansion (Fig. 5D). The incomplete inhibition of cDC expansion in Rag1–/– mice depleted 
of NK cells and ILCs is likely due to tissue residency of ILCs, which are incompletely 
amenable to antibody-mediated depletion (43). 
 To further study the contribution of ILCs to IL-2–induced cDC proliferation, we 
reconstituted sublethally irradiated (450 RAD) Il2rg–/– and Il2rg–/– Rag2–/– mice with ILC2 
precursor (ILC2p) cells (Fig. 5E and fig. S5F) (43-45). Two months later, ILC2p cells had 
developed to all ILC subsets but not into B, T, and NK cells (Fig. 5F, upper panel). 
Although sorted ILC2p cells were used for the reconstitution of Il2rg–/– Rag2–/– mice, we 
detected not only ILC2s, but also RORγt+ ILC3s and RORγt– GATA3– ILC1s (Fig. 5F, 
upper panel). Control mice reconstituted with common lymphoid progenitor (CLP) cells 
harbored all ILC subsets, as well as B, T, and NK cells (Fig. 5F, lower panel). Subsequent 
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treatment with IL-2cx induced the expansion of splenic cDCs in ILC2p-reconstituted mice 
(Fig. 5G). 
 To investigate whether lymphoid cells produced cDC-active cytokines, we 
measured intracellular RNA transcripts of FLT3L, CSF2 and TNF with flow cytometry, 
which showed that T, NK cells, and ILCs produced Flt3l at steady state (Fig. 5H). IL-2 
treatment of mice further stimulated production in CD4+ Treg, CD8+ T, and NK cells, but 
not in CD4+ Tcon cells and ILCs (Fig. 5H). Under steady-state conditions, low amounts of 
Csf2 transcripts were detected, and IL-2cx treatment of mice induced expression in NK 
cells, ILC1, and ILC2, but not in T cells and ILC3 (Fig 5H). IL-2 treatment of mice 
increased intracellular Tnf in all subsets (Fig. 5H). 
Intracellular assessment of CSF2 and TNF upon in vitro stimulation confirmed 
expansion of CSF2+ and TNF+ cells in all investigated lymphocyte subsets and ILCs, 
except for TNF+ CD4+ Tcon cells, which did not expand (Fig. 5, I and J). Together, these 
results demonstrated that IL-2 stimulates innate and adaptive lymphoid cells to produce 
DC-active cytokines, which then stimulate the expansion of cDCs. 
 
IL-2 immunotherapy-activated cDCs facilitate anti-tumor responses in mouse and 
human 
We investigated the effects of IL-2 treatment on the function of cDCs. Treatment of mice 
with IL-2cx induced upregulation of CD40, CD80, CD86, and MHC class I (MHC-I), but 
not MHC-II, on cDCs (Fig. 6A). These changes are indicative of mature cDCs with 
increased potential of cross-presentation and co-stimulation for T cell activation (10, 46, 
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47). RNA-seq data confirmed that cDCs from IL-2–treated animals showed upregulation 
of genes associated with antigen processing and presentation (fig. S6A). 
 To measure antigen uptake and processing, we used DQ-ovalbumin in which 
fluorescence is an indirect measure of lysosomal degradation of ovalbumin in cDCs. 
Compared with cDCs from untreated mice, cDCs from IL-2cx–treated mice showed greater 
antigen uptake and processing after 24, 48, and 72 hours of in vitro culture (Fig. 6B). 
 Based on these data, we hypothesized that cDCs from IL-2–treated mice have 
greater capacity to activate T cells than those from untreated mice. We isolated cDCs from 
untreated or IL-2cx–treated mice, incubated these cells with a 24-amino-acid-ovalbumin 
peptide (DEVSGLEQLESIINFEKLAAAAAK) with improved cross-presentation 
properties (48), and adoptively transferred these cDCs into naïve mice by footpad injection. 
After 24 hours, carboxyfluorescein succinimidyl ester (CFSE)-labelled antigen-specific 
OT-1 CD8+ T cells were adoptively transferred into the mice and the proliferation of these 
T cells was assessed 2 – 3 days later (Fig. 6C). The results confirmed our hypothesis: cDCs 
from IL-2cx–treated animals induced significantly more expansion of OT-1 CD8+ T cells 
(Fig. 6C; P = 0.0206). 
 To investigate whether IL-2 immunotherapy expanded tumor-infiltrating cDCs, we 
quantified cDCs in B16-F10 melanoma-bearing mice receiving IL-2cx (fig. S6B). Tumor-
infiltrating CD103+ cDC1s and cDC2s were increased on day 11 after tumor implantation, 
and tumor growth was delayed in IL-2cx–treated compared to growth in untreated mice 
(Fig. 6D). On the contrary, anti-PD-1 antibody treatment neither increased tumor-
infiltrating CD103+ cDC1s or cDC2s, nor delayed tumor growth compared to untreated 
animals (Fig. 6D and fig. S6C). The failure of anti-PD-1 monotherapy to reduce growth of 
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B16-F10 melanoma is consistent with observations of other groups (49, 50). Further 
analyzing these data, we observed a negative linear correlation between tumor-infiltrating 
cDC1 and tumor volume (Fig. 6E). We did not observe a significant correlation for tumor-
infiltrating cDC2 (Fig. 6E; P = 0.0872). We observed increased numbers of tumor-
infiltrating cDC1 and cDC2 in the inducible melanoma model BrafCA PtenloxP 
Tyr::CreERT2 (Fig. 6F). 
 To clarify the role of cDCs in orchestrating IL-2–mediated anti-tumor responses, 
we evaluated B16-F10 melanoma growth in two different DC-depletion models: The 
Cd11c-DTR model, which depletes all CD11c+ cells upon administration of diphtheria 
toxin (DT), and the Zbtb46-DTR model, which specifically depletes cDCs (3). In bone 
marrow chimeras generated using these transgenic mice, IL-2cx–mediated tumor control 
was lost when DCs were continuously depleted beginning 1 day before tumor implantation 
(Fig. 6, G and H, and fig. S6, D and E). DC-depleted mice not receiving immunotherapy 
did not show accelerated tumor growth compared with mice that were not DC depleted, 
likely due to the aggressive growth of B16-F10 melanoma. Similar to the other B16-F10 
results (Fig. 6D), anti-PD-1 treatment did not delay tumor growth. 
Analyzing TCGA data of human skin cutaneous melanoma revealed prolonged 
survival of patients with tumors with a high IL-2 signature, consisting of IL2 and 10 IL-2–
induced genes (51) (50% threshold; Fig. 6I). We observed a similar trend for patients with 
BATF3high tumors (Fig. 6I). Notably, the hazard ratio for tumors with high expression of 
the IL-2 signature was even lower than that for BATF3high tumors (hazard ratio 0.57 and 
0.68, respectively), suggesting the IL-2 signature has a better predictive value. Further data 
mining uncovered a positive relationship between the IL-2 signature and BATF3 (Fig. 6J). 
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Other correlations were found between BATF3 and CD4, CD8B, and an NK cell signature 
(Fig. 6K). BATF3 also correlated with the CSF2-FLT3L-TNF cytokine signature and the 
individual cytokines CSF2, FLT3L, and TNF (Fig. 6L). More detailed analysis revealed a 
positive correlation between IL2 and BATF3 as well as between each IL2R subunit 
transcript and BATF3 (fig. S6F). 
 Altogether, these data showed that IL-2 immunotherapy promotes activation and 
expansion of tumor-infiltrating cDCs, which enhances antigen presentation and CD8+ T 




Previous seminal studies established a crucial role of intratumoral CD103+ cDCs in 
stimulating CD8+ T cells for efficient anti-tumor responses (8-11). These cells depend on 
FLT3L, CSF2, BATF3, and IRF8. However, these cells are extremely rare in the TME. 
Our work identified an IL-2–lymphoid cell–cDC pathway that robustly expands and 
stimulates this BATF3+ IRF8+ CD103+ cDC1 subset. This pathway depended on 
production of FLT3L, CSF2, and TNF by several ILC subsets, NK cells, and T cells. These 
DC-active cytokines induced differentiation of DC precursors, as well expansion and 
activation of mature cDCs. Thus, our findings extend work showing that NK cells attract 
DCs into the TME by secreting XCL1 and CCL5 (15) and serve as the main producers of 
FLT3L in mouse melanoma (16). Moreover, we showed that the IL-2–lymphoid cell–cDC 
pathway stimulates and expands cDC2s, which have been implicated in priming anti-tumor 
CD4+ T cell responses (46). Although FLT3L and CSF2 play critical roles in cDC 
expansion (28, 38), TNF induces cDC maturation that is critical for efficient anti-viral 
responses (52). Our findings suggested a role for TNF in cDC differentiation in vivo, 
supporting previous studies showing such an effect in vitro where TNF skews 
differentiation of precursors from monocytes to DCs by inhibiting the IL-6/CSF1 pathway 
(53). 
 Some previous studies suggested that DCs have functional IL-2R and that IL-2 has 
a direct effect on DC development in vitro (54, 55); other studies provided somewhat 
contradictory data based on the absence of CD122 on DCs (56-58). Mouse (59) and human 
(60) DCs can have detectable CD25, especially upon stimulation with TLR ligands (36, 
37) or following culture with CSF2 (56). Functionally, upregulation of CD25 on activated 
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DCs could facilitate trans-presentation of IL-2 to T cells early during T cell activation (61, 
62). Concerning CD122, most studies suggest that directly isolated or CSF2-cultured 
mouse and human DCs do not have detectable CD122 (56-58). Nevertheless, two carefully 
conducted in vitro studies suggested an inhibitory role of IL-2 on FLT3L-mediated DC 
differentiation from mouse bone marrow (54, 55). The discrepancy between the observed 
inhibitory effect of IL-2 and our study might be explained by the different conditions, 
cytokines, and other growth factors in vitro versus in vivo. Here, neither directly isolated 
DCs nor DC precursors had CD122, even after in vivo IL-2 or TLR ligand treatment. 
Furthermore, we could not detect activation of the IL-2 signaling pathway after incubation 
of DCs and DC precursors with high concentrations of IL-2, which to our knowledge has 
not been shown in previous studies claiming functional IL-2Rs on DCs. Thus, DCs and DC 
precursors do not have functional IL-2Rs. Finally, Il2rg–/– cDCs expanded equally to 
Il2rg+/+ cDCs in bone marrow chimeric mice upon IL-2 treatment, strongly supporting our 
model of indirect DC expansion through secondary secretion of DC-active cytokines upon 
IL-2 treatment in vivo. 
 Our work thus uncovers an aspect of IL-2–mediated anti-tumor responses beyond 
the direct effects on IL-2–responsive effector cells. One could speculate that IL-2 treatment 
might turn poorly immune infiltrated, that is 'cold', tumors into highly infiltrated, 'hot' 
tumors, which are responsive to immune checkpoint inhibitors. In line with this suggestion, 
IL-2 immunotherapy in melanoma-bearing mice increases intratumoral TNF and CCL5 
production and PD-1 ligand (PD-L1) abundance on cancer cells, thus rendering the tumor 
hot (39). Moreover in patients, treatment with the PEGylated IL-2 molecule 
bempegaldesleukin (also known as NKTR-214) increased PD-L1 on previously PD-L1–
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negative urothelial cancer biopsies after 3 weeks of treatment, indicating the conversion of 
a cold to a hot TME (63). 
 Furthermore, our data could explain why IL-2 immunotherapy has in some patients 
resulted in remarkably long-term anti-tumor responses lasting 20 years and more (64). This 
finding could indicate the priming and programming of long-lived memory CD8+ and 
CD4+ T cells during IL-2 immunotherapy by direct IL-2 signals (65) and restimulation of 
CD8+ and CD4+ T cells by IL-2–mediated expansion of intratumoral cDC1s and cDC2s. 
Based on this suggestion, we hypothesize that the herein-described adaptive cDC-poiesis 
could affect the generation and development of long-lived memory CD8+ T cells. These 
suggestions might also apply to bacterial and viral infections. Thus, early cDCs presenting 
high loads of antigens could prime T cells to preferentially adopt a short-lived effector fate, 
whereas a second wave of cDCs due to the IL-2–lymphoid cell–cDC pathway could result 
in cDCs carrying lower concentrations of antigenic peptides, thereby inducing memory T 
cells. 
Future studies should address the following limitations of our study. Our patient 
tumor results are derived from the TCGA database and reflect correlations between 
different gene signatures. It would be interesting to extend our investigations to melanoma 
patient samples from tumors and secondary lymphoid tissues, ideally in a paired manner 
before and after high-dose aldesleukin treatment. However, these samples are very difficult 
to obtain as aldesleukin has rarely been used for cancer immunotherapy to date. 
Furthermore, our investigations have focused on mouse and human melanoma. Assessment 
of other cancer types following IL-2 immunotherapy could reveal a similar pathway that 
results in DC expansion. Another topic concerns depletion of ILCs. Using monoclonal 
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antibodies targeting NK cells and ILCs only partially abrogated IL-2cx–mediated DC 
expansion. This could be due to incomplete depletion of tissue-resident ILCs, which should 
be assessed in future studies using transgenic mouse models allowing specific and complete 
depletion of selective ILC subsets. 
 In summary, our work further sheds light on an IL-2 immunotherapy-mediated IL-
2–lymphoid cell–cDC pathway (fig. S7). Our findings support the investigation of potential 
combinatorial approaches in which IL-2 treatment could render poorly immunogenic 
cancers amenable to treatment with immune checkpoint inhibitors. 
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MATERIALS AND METHODS 
Study design 
The aim of this study was to assess the mechanism of IL-2–mediated DC expansion in mice 
and humans. To this end, we used different mouse models, blood samples collected from 
IL-2–treated patients, and publicly available datasets. Sample size was chosen empirically 
based on results of previous studies. Reporting of mouse studies followed the Animal 
Research: Reporting of In Vivo Experiments (ARRIVE) guidelines. In general, 
experiments aimed to include in total 10 mice per group and were repeated three times with 
precise numbers for each individual experiment provided in the figure legends. Mice were 
randomly assigned to different treatment groups and stratified according to gender and age. 
Investigators were not blinded. No data outliers were excluded. Primary data are reported 
in data file S1. 
 
Clinical trial and human samples 
Human samples were collected within the clinical trial “Open-label, Monocentric, Phase 
II, Investigator-initiated Clinical Trial on Unbiased Characterization of Immunological 
Parameters in Interleukin-2-treated Systemic Lupus Erythematosus” (Charact-IL-2, 
ClinicalTrials identifier: NCT03312335) and the “Fundamental research project for 
phenotypical and functional characterization of different leukocyte subsets in healthy and 
diseased individuals” (PFCL-1, BASEC no. 2016-01440). Both projects have been 
reviewed and approved by the competent Swiss authorities and have been carried out in 
accordance with principles enunciated in the current version of the Declaration of Helsinki, 
the guidelines of Good Clinical Practice, and Swiss legal requirements. Prior to enrollment 
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into the clinical trial or sample collection, written informed consent was obtained. Human 
blood was collected into EDTA Vacutainer tubes (BD Biosciences) followed by Ficoll-
Paque PLUS (GE Healthcare) gradient centrifugation for peripheral blood mononuclear 
cell (PBMC) isolation. Isolated PBMCs were frozen in fetal calf serum (FCS, Gibco) 
containing 10% dimethyl sulfoxide (Sigma) and stored for less than 1 year in liquid 
nitrogen prior to analysis. Serum was isolated from blood collected with Clot Activator 
Vacutainer tubes (BD Biosciences) and stored for less than 18 months at –80°C prior to 
analysis. 
 For evaluation of IL-2–mediated expansion of cDCs and lymphocytes, blood from 
patients with systemic lupus erythematosus (SLE) was collected prior and after a 5-day 
course of daily 1.5 million international units (MIU) of aldesleukin (Proleukin®, Novartis 
Pharma), according to the study protocol. 
 
Mice 
C57Bl/6J mice were purchased from Charles River Laboratories. Tcrbd–/– (JAX stock no. 
002122), Rag1–/– (JAX stock no. 002216), Csf2–/–, Flt3l–/–, CD45.1+ (JAX stock no. 
002014), Il2ra–/– (JAX stock no. 002462), Il2rb–/– (JAX stock no. 002816), Il2rg–/– (JAX 
stock no. 003174), Rag2–/– Il2rg–/– (Taconic stock no. 4111), OT-1 (JAX stock no. 003831), 
Cd11c-DTR (JAX stock no. 004509), Zbtb46-DTR (JAX stock no. 019506), Tnfrsf1a/b–/– 
(JAX stock no. 003243), Foxp3-GFP-DTR (JAX stock no. 016958), and BrafCA PtenloxP 
Tyr::CreERT2 (JAX stock no. 013590) were obtained from the Jackson Laboratory (JAX) 
or from the Swiss Immunology Mouse Repository. Csf2–/– (JAX stock no. 026812) and 
Flt3l–/– (MMRRRC stock no. 37395-JAX) mice were generously provided by M. Manz 
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(University Hospital Zurich) and A. Rolink (University of Basel), respectively, and crossed 
to generate Csf2–/– Flt3l–/– mice. Female and male mice were used for experiments at 2 – 5 
months of age. The experiments were conducted in a randomized fashion by unblinded 
investigators. Mice were held in a specific pathogen free (SPF) facility at the University 
Hospital Zurich according to institutional guidelines. Animal experiments received prior 
approval by the veterinary office of the Canton of Zurich (License numbers 142/2017 and 
246/2016) and were conducted in accordance with Swiss Federal and Cantonal Law. 
 
In vivo treatments 
Recombinant human IL-2 (teceleukin, Roche) was obtained from the National Cancer 
Institute of the National Institutes of Health. IL-2/NARA1 (IL-2cx) and IL-2/5344 
antibody complexes were prepared by mixing 15,000 IU IL-2 and 15 µg anti-IL-2 
monoclonal antibodies (mAbs) per injection, as previously described (22-24). IL-2cx, IL-
2/5344 antibody complexes, or 200,000 IU IL-2 were injected daily for three consecutive 
days unless stated otherwise. Where mentioned, depletion of specific immune cells was 
performed using 250 µg anti-NK1.1 mAb (clone PK136, Leinco Technologies) and 500 µg 
anti-Thy1.2 mAb (clone 30H12, BioXcell). Depleting mAbs were administered 
intraperitoneally daily throughout the experiment starting one day before treatment 
initiation with IL-2 complexes. For in vivo activation of DCs, 100 µg polyinosinic–
polycytidylic acid (Poly I:C; Sigma-Aldrich) and 100 µg Pam3Csk4 (InvivoGen) was 
injected daily for three consecutive days. 
 To determine immune cell proliferation, bromodeoxyuridine (BrdU; B5002, 
Sigma-Aldrich) was given to mice either by daily i.p. injection (1 mg/injection) or in 
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drinking water (0.8 mg/ml), as established (66). BrdU-incorporated cells were labeled 
using the FITC BrdU Flow Kit (BD Biosciences) according to manufacturer’s instructions. 
 Where indicated, 500µg etanercept (Enbrel®, Pfizer) was injected concomitantly 
with IL-2cx for three consecutive days. 
 
Flow cytometry 
Single cell suspensions of lymph nodes, spleens, and bone marrow were prepared 
according to standard protocols. For all experiments evaluating DCs, organs were digested 
in PBS containing 1 mg/ml collagenase D (Roche) for 15 min in the incubator at 37°C. 
Tumors were cut into small pieces and incubated in 10 ml dissociation buffer (RPMI, 5% 
FCS, 10 µg/ml DNAse I (Sigma-Aldrich) and 200 U/ml collagenase type I (Thermo Fisher 
Scientific) for 60 min at 37°C, shaking with 25 rpm. Cell suspensions were then passed 
through a 70-μm cell strainer. In experiments with intradermally implanted tumors, after 
one wash a Percoll (40% and 70%; GE Healthcare) gradient centrifugation was performed. 
All cell suspensions were stained for flow cytometry analysis using flow cytometry buffer 
(PBS with 2% FCS, 2 mM EDTA) and fluorochrome-conjugated antibodies for at least 20 
min at 4°C. A list of used antibodies is provided in table S1. Intracellular staining with 
Ki67, FOXP3, GATA3, RORγt, TBET, BAX, BCL-2, CSF2, and TNF was performed 
following manufacturer’s instructions using the eBioscience™ Foxp3 / Transcription 
Factor Staining Buffer Set (ThermoFisher). Caspase-3 was measured with the Active 
Caspase-3 Apoptosis Kit (BD Biosciences) according to manufacturer’s instructions. 
Annexin V and 7-AAD live and dead cell staining was conducted according to the 
instructions of the Annexin V Apoptosis Detection Kit with 7-AAD (BioLegend). 
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 For STAT5 phosphorylation analysis, freshly isolated mouse splenocytes or human 
PBMCs were incubated for 25 min at 37°C as indicated with either mouse CSF2 
(Peprotech), human CSF2 (Peprotech), or IL-2 (teceleukin, Roche). Cells were directly 
fixed with paraformaldehyde (Sigma-Aldrich, final concentration 1.5%) followed by 
permeabilization with methanol (Cantonal Pharmacy Zurich) and staining with 
fluorochrome-conjugated antibodies in flow cytometry buffer. 
 Cell cycle analysis was conducted with FxCycle PI/RNase Staining Solution 
(Thermo Fisher Scientific) after ethanol fixation (Cantonal Pharmacy Zurich, final 
concentration 70%) according to manufacturer’s instruction. 
 Intracellular RNA was measured with PrimeFlow RNA assay (Thermo Fisher 
Scientific) with target probes against Actb (Ref 60384), Flt3l (Ref 64644), Csf2 (Ref 
64983), and Tnf (Ref 60209) according to manufacturer’s instructions. 
 Samples were acquired with a BD FACS Canto II, BD LSR II, or BD 
FACSymphony flow cytometer (BD Biosciences) and analyzed using FlowJo software 
(BD Biosciences). Where indicated, fluorescence-activated cell sorting (FACS) was 
performed using a BD FACS Aria III 5L (BD Biosciences). 
 
Generation of bone marrow chimeras 
Bone marrow chimeric mice were generated by adoptive transfer of 1 – 2 × 106 lineage 
(Lin)-depleted bone marrow cells from donor mice into lethally (950 RAD) irradiated host 
mice. Lineage depletion was done by magnetic negative selection (MoJoSort Streptavidin 
Nanobeads, BioLegend) with biotinylated antibodies targeting CD3, CD19, NK1.1, and 
Ter119 (all from BioLegend). For ILC reconstitution experiments, ILCp (CD127+ α4β7+ 
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CD25+ CD135– CD117–) and, where indicated, CLPs (CD127+ α4β7– CD135+) were 
FACS-sorted from Lin– (CD3, CD4, CD5, CD8, CD11b, CD11c, CD19, CD335, B220, 
Gr-1, Ter119, NK1.1, F4/80) bone marrow, followed by adoptive transfer into sublethally 
(450 RAD) irradiated Il2rg–/– or Il2rg–/– Rag2–/– mice. All mice were rested for at least 6 – 
8 weeks prior to treatment with IL-2cx. 
 
Cell cultures 
For DQ-ovalbumin assays, splenocytes were isolated as described above followed by 
incubation in DQ-ovalbumin (Life Technologies) at a concentration of 50 µg/ml in full 
RPMI medium [RPMI (Gibco) containing 10% FCS (Gibco), 4 mM L-glutamine (Thermo 
Fisher Scientific), and Penicillin-Streptomycin (Thermo Fisher Scientific)] for the time 
indicated. 
 For intracellular TNF or CSF2 measurements in lymphocytes, splenocytes of wild-
type mice were stimulated for 4 or 8 hours in full RPMI medium containing either 50 ng/ml 
phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich), 0.5 µg/ml ionomycin (Sigma-
Aldrich), and 10 µg/ml brefeldin A (BFA, Sigma-Aldrich) for TNF evaluation; or 100 
ng/ml PMA, 1 µg/ml ionomycin, and 2 µM monensin (BioLegend) for CSF2 evaluation. 
For intracellular TNF and CSF2 measurements in ILCs, splenocytes of Tcrbd–/– mice were 
stimulated for 6 hours in full RPMI medium containing 100 ng/ml PMA, 1 µg/ml 
ionomycin (Sigma-Aldrich), and 10 µg/ml brefeldin A (BFA, Sigma-Aldrich). 
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Adoptive DC transfer by intrasplenic injection 
For studies assessing the persistence of mature DCs, cell trace violet-labeled (labeling for 
7.5 min at 37°C; Thermo Fisher Scientific), magnetically purified CD11c+ (MoJoSort 
Mouse CD11c Nanobeads, BioLegend) splenocytes isolated from untreated or IL-2cx–
pretreated CD45.1+ or CD45.2+ mice were adoptively transferred by subcapsular injection 
into the spleen of either untreated (Fig. 2F) or IL-2cx–pretreated recipients (Fig. 2G). IL-
2cx–treated donors received IL-2cx on three consecutive days before isolation of 
splenocytes, whereas IL-2cx–treated recipients received IL-2cx on three consecutive days 
with the last injection coinciding with the day of adoptive DC transfer. 
 
OT-1 proliferation 
CD45.1 mice were treated with IL-2cx for 3 consecutive days or left untreated followed by 
isolation of splenocytes and magnetic purification of CD11c+ cells with (MojoSort Mouse 
CD11c Nanobeads, BioLegend). Isolated cells were incubated in RPMI (Gibco) containing 
10% FCS (Gibco), 4 mM L-glutamine (Thermo Fisher Scientific), Penicillin-Streptomycin 
(Thermo Fisher Scientific), and 50 µg/ml ovalbumin peptide 
(DEVSGLEQLESIINFEKLAAAAAK, obtained from the peptide synthesis facility of 
Leiden University Medical Center) for 2 hours before injection into the foot pad of CD45.2 
recipient mice (48). 2-3 x 106 purified and carboxyfluorescein succinimidyl ester (CFSE; 
Thermo Fisher Scientific)-labeled OT-1 T cells were adoptively transferred to recipients 




The mouse B16-F10 (CRL-6475, ATCC) cell line was cultured in Advanced DMEM 
(Gibco) containing 10% FCS (Gibco), 4 mM L-glutamine (Thermo Fisher Scientific), and 
Penicillin-Streptomycin (Thermo Fisher Scientific). Recipient mice were intradermally 
engrafted with 1 × 106 B16-F10 cells. Treatment was started when tumor nodules were 
visible and palpable on day 4 after tumor inoculation by using IL-2cx or 100 µg anti-PD-1 
(clone RMP1-14, Leinco Technologies) injected every other day (fig. S6B, upper panel) 
(24). Mice were euthanized on day 11 for isolation of tumor-infiltrating lymphocytes. For 
evaluating tumor growth under DC-deficient conditions, lethally irradiated C57Bl/6J host 
mice were reconstituted with Lin-depleted Cd11c-DTR or Zbtb46-DTR bone marrow, as 
described above, followed by treatment with 0.5 µg DT (Sigma-Aldrich) 3× weekly 
starting one day prior to tumor inoculation. IL-2cx and anti-PD-1 treatment was 
continuously administered 3× weekly starting day 4 after tumor inoculation (fig. S6B, 
lower panel). Tumor volume was calculated according to the following formula: V = 2/3 × 
π × ((a + b)/4)3, a (mm) was the length and b (mm) was the width of the tumor. 
 For inducible tumors, BrafCA PtenloxP Tyr::CreERT2 mice were topically applied 
on the skin with 2 µl of 25 mg/ml 4-hydroxytamoxifen (≥70% Z isomer, Sigma-Aldrich) 
dissolved in dimethyl sulfoxide (Sigma-Aldrich) on three consecutive days. Approximately 
21 – 28 days later when tumor nodules have formed, mice were treated with IL-2cx or anti-




Serum samples from mice were collected and stored at -80°C until cytokine testing. Serum 
cytokine concentrations were determined using Mouse GM-CSF ELISA MAX Standard 
(BioLegend), Mouse TNF-alpha Quantikine HS ELISA kit (R&D Systems) and Mouse Flt-
3L ELISA Kit (Thermo Fisher Scientific). Measurements were performed in accordance to 
manufacturer’s instructions. 
 Human serum samples before and after aldesleukin treatment were collected and 
stored as described before. GM-CSF was measured using Human GM-CSF ELISA MAX 
Standard (BioLegend). Human FLT3L and TNF were measured with proximity extension 
assay using the Olink Inflammation Panel. 
 
Gene expression correlation analyses 
For mouse Il2r expression analysis, RNA-seq and microarray data were retrieved from the 
ImmGen database (40) and plotted as relative expression in indicated immune cell subsets. 
 The RNA-seq data set for skin cutaneous melanoma was downloaded with 
Firebrowse (The Broad Institute) from The Cancer Genome Atlas (TCGA) (67). Gene 
expression was log2-transformed (log2[gene expression + 1]) and different genes of 
interest were correlated against each other. For gene signatures, the mean expression of all 
signature genes was calculated and plotted against BATF3 expression. The NK cell 
signature was defined by the genes NCR1, NCR3, KLRB1, CD160, and PRF1 (15). The IL-
2 signature was defined by the IL-2-target genes LTA, ARHGDIA, PKD2, LTB, KLF6, 
PDIA3, GZMB, PSMB1, S100A4, and FLT3LG (51); and IL2. Significance of correlative 
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gene expression was calculated by using Pearson’s correlation coefficient. Survival 
analysis was done with gene expression profiling interactive analysis 2 (68). 
 
Quantitative polymerase chain reaction (qPCR) 
RNA was isolated with the RNeasy Plus Micro and Mini Kits (Qiagen) from 250’000-
1’000’000 FACS sorted cDCs (CD3– CD19– NK1.1– CD45RB– MHC-II+ CD11c+), CD4+ 
conventional T (Tcon; CD3+ CD4+ Foxp3–) and CD4+ regulatory T cells (Treg; CD3+ CD4+ 
Foxp3+) from Foxp3-GFP-DTR mice. Control RNA was isolated from untreated bulk wild-
type, Il2ra–/–, Il2rb–/–, and Il2rg–/– splenocytes. After cDNA reverse transcription (High 
Capacity cDNA Reverse Transcription Kit, Applied Biosystems), qPCR analysis was 
performed using SYBR green (KAPA SYBR FAST, Roche) on a 7900HT Fast Real-Time 
PCR System (Applied Biosystems) and ΔΔCt values calculated. The following primer 
sequences were used:  
Hprt (forward: GAT CAG TCA ACG GGG GAC AT, reverse: ATC CAA CAA AGT CTG 
GCC TGT),  
Il2ra (forward: AAC CAT AGT ACC CAG TTG TCG G, reverse: TCC TAA GCA ACG 
CAT ATA GAC CA),  
Il2rb (forward: TGG AGC CTG TCC CTC TAC G, reverse: TCC ACA TGC AAG AGA 
CAT TGG),  
Il2rg (forward: GGT TAC TGA ATA CCA AGG GAA CTT T, reverse: TGG CAG AAC 
CGT TCA CTG TA). 
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RNA sequencing (RNA-seq) 
Forty thousand splenic mouse cDCs from untreated and IL-2cx–treated wild-type mice 
were separated by FACS in RLT Plus lysis buffer (Qiagen) containing 1% 2-
mercaptoethanol (Sigma-Aldrich). Subsequently, RNA was isolated using the RNeasy Plus 
Micro Kit (Qiagen). RNA-seq and data processing was done by the Functional Genomics 
Center Zurich, as briefly described here. The RNA extracted from sorted cells was 
quantified for quality and concentration using the TapeStation RNA high sensitivity kit 
(Agilent). The estimated RINs were in a range of 8.4 – 9.8 showing a good RNA quality; 
the RNA concentrations of 1.1 – 10 ng/µl recommended the use of a low input library 
preparation method. Accordingly, the SMARTer Stranded Total RNA Seq Kit v2 (Takara 
Bio) was used to prepare cDNA by universal priming (with 3 min fragmentation) and to 
deplete ribosomal cDNA with ZapR v2 and R Probes v2. The libraries were quantified by 
Tapestation D1000 (Agilent) measurements, and they showed fragment sizes around 320 
bp. The libraries were sequenced on a HiSeq 4000 platform using 125 cycles single-read 
targeting ~40M reads per sample. Adapters and low-quality tails were trimmed from reads 
prior to read alignment. STAR aligner (v2.5.4b) (69) was used to align the RNA-seq dataset 
to Ensembl genome build GRCh38.p10 (Release 91). Gene expression counts were 
calculated with feature counts from Bioconductor package Rsubread (v1.32.1) (70). A gene 
was considered as expressed if, in at least one group of the comparison, it had more than 
10 counts in more than half of the samples. Differentially expressed genes were detected 
using Bioconductor package EdgeR (v3.20.6) (71). Gene set enrichment analysis was done 
with Gene Ontology analyzer for RNA-seq and other length-biased data (goseq, v1.30.0) 
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(72). For the heatmap display, the top 75 up-regulated and top 75 down-regulated genes 
were log2-transformed (log2[normalized gene count + 1]) for calculation of Z-scores. 
 
Software 




Detailed information on sample numbers and statistical tests used are described in the 
figure legends. Calculation was performed with the GraphPad Prism 8 software package. 
In general, differences between two groups were tested with t-tests for normally distributed 
data or Mann-Whitney test for not normally distributed data. Multiple comparison was 
done with either one-way ANOVA followed by Holm-Sidak’s multiple comparison test for 
normally distributed data or Kruskall-Wallis test followed by Dunn’s multiple comparison 
test for not normally distributed data. Time-dependent comparisons were tested with two-
way ANOVA or mixed-effects model, followed by Holm-Sidak’s multiple comparison 
test. Normality testing was done using d’Agostino-Pearson test. Correlation analysis was 
done with Pearson correlation coefficient and survival analysis with Logrank test. For all 
statistical analyses, significance was accepted at the 95% confidence level (P < 0.05). Exact 
P-values are provided; n.s. indicates not significant.  
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SUPPLEMENTARY MATERIALS 
- Fig. S1. Different IL-2 formulations cause cDC1 and cDC2 expansion. 
- Fig. S2. Apoptosis-mediating proteins in cDCs do not change after IL-2cx treatment. 
- Fig. S3. IL-2 receptor (IL-2R) expression in stimulated cDCs and IL-2cx-treated cDCs 
and DC precursors. 
- Fig. S4. Expansion of cDC subsets in Flt3l–/– Csf2–/– mice and cDC proliferation in 
etanercept-treated wild-type mice. 
- Fig. S5. IL-2 receptor expression on different leukocytes and expansion of CD4+ T, 
CD8+ T and NK cells by IL-2 complexes. 
- Fig. S6. DCs show improved antigen processing and facilitate anti-tumor responses 
after IL-2cx treatment. 
- Fig. S7: Model of IL-2–mediated DC expansion and tumor infiltration. 
- Table S1: Antibodies and fluorescent dyes used for flow cytometry. 
- Data file S1: Primary data. 
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Fig. 1. IL-2 immunotherapy expands cDCs in mice and humans. 
(A) Representative gating strategy for mouse splenic DC subsets including plasmacytoid 
DCs (pDC) and conventional type I and type II DCs (cDC1 and cDC2). (B) Total splenic 
cDC counts after treatment with IL-2 or IL-2 complexes (IL-2cx) in wild-type (WT) mice. 
Data are presented as mean +/- SEM (n = 7 to 9 mice per group from N = 3 independent 
experiments). (C) Proliferation of splenic cDCs from mice receiving the indicated 
treatments was measured by bromodeoxyuridine (BrdU) incorporation over 3 days. Data 
are presented as mean +/- SEM (n = 7 mice per group from N = 3 independent experiments). 
(D and E) Quantification of total numbers (D) and proliferation (E) of splenic cDC subsets 
from mice receiving the indicated treatments. Data are presented as mean +/- SEM (n = 19 
(D) and 16 (E) mice per group from N = 8 (D) and 6 (E) independent experiments). (F) 
Study design of the investigator-initiated clinical trial testing 1.5 million international units 
(MIU) aldesleukin (recombinant human IL-2) injected subcutaneously daily on 5 
consecutive days with blood draws before and after aldesleukin injection (upper panel). 
Corresponding gating strategy of human cDC subsets identifying CD141+ cDC1 and 
CD1c+ cDC2 (lower panel). (G) Percentages of Ki67+ proliferating cDC1 (n = 8) and cDC2 
(n = 10) in peripheral blood from patients before and after aldesleukin treatment. (H) 
Biological processes Gene Ontology (GO) terms enriched in RNA-seq data of IL-2cx-
treated WT mice compared to untreated mice (n = 4 mice per group from 1 experiment). 
The numbers in parentheses refer to the count of significantly upregulated genes within 
each GO term. (I) Top 75 upregulated (top panel) and top 75 downregulated (bottom panel) 
genes in IL-2cx-treated WT mice compared to untreated mice. P-values calculated with 
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Kruskall-Wallis test with Dunn's multiple comparison test (B), Mann-Whitney test (D and 
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Fig. 2. IL-2 causes proliferation of mature cDCs and differentiation of DC precursors. 
(A) Cell cycle analysis of splenic cDCs from IL-2cx-treated and untreated wild-type mice 
with the Watson model for cell cycle analysis for each cell cycle state including gap 0 (G0), 
gap 1 (G1), synthesis (S), gap 2 (G2), and mitosis (M). Data are presented as mean +/- 
SEM (n = 7 mice per group from N = 3 independent experiments). (B) Representative 
pseudocolor plots of bone marrow cells from untreated mice showing gating strategy for 
identifying monocyte/DC progenitor (MDP) cells, common dendritic cell progenitor 
(CDP) cells, precursor (pre)-cDC1, and pre-cDC2. (C) Total counts of precursor 
populations in bone marrow cells in mice receiving indicated treatments. Data are 
presented as mean +/- SEM (n = 11 mice per group from N = 3 independent experiments). 
(D) Total cell counts of splenic cDC1 and cDC2 from matched mice described in (C). Data 
are presented as mean +/- SEM (n = 11 mice per group from N = 3 independent 
experiments). (E) Activated caspase-3 in cDCs from untreated and IL-2cx–treated mice. 
Data are presented as mean +/- SEM (n = 4 to 5 mice per group from N = 2 independent 
experiments). (F) Survival of mature cDCs 48 hours after adoptive transfer of cDCs from 
both untreated and IL-2cx–treated donors into untreated recipient mice by intrasplenic 
injection. Data are presented as mean +/- SEM (n = 10 mice per group from N = 4 
independent experiments). (G) Survival of mature cDCs 48 hours after adoptive transfer 
by intrasplenic injection of cDCs from untreated donor into either untreated or IL-2cx-
pretreated recipient mice. Data are presented as mean +/- SEM (n = 8 to 9 mice per group 
from N = 2 independent experiments). P-values were calculated using multiple t-tests (A 
and D), Mann-Whitney test (C) or unpaired t-test (E to G). 
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Fig. 3. Mature DCs and their precursors lack functional IL-2Rs. 
(A) Relative mRNA expression of Il2ra (encoding CD25), Il2rb (CD122), and Il2rg 
(CD132) in cDCs from untreated (black dots) and IL-2cx-treated (red dots) mice compared 
to the expression in conventional T (Tcon) and regulatory T (Treg) cells from the same 
mice (n = 2 mice per group and treatment condition). Control conditions included 
splenocytes isolated from untreated wild-type (WT), Il2ra–/–, Il2rb–/–, and Il2rg–/– mice (n 
= 1 mouse per group). Data are presented as mean +/- SEM (N = 1 independent experiment 
with 4 technical replicates per mouse). (B) IL-2R subunit abundance on the surface of 
mouse splenic cDCs (left panel) and Treg cells (right panel) by flow cytometry. Displayed 
are representative histograms from n = 9 mice and N = 3 independent experiments showing 
the intensity of IL-2R subunit staining in untreated (blue line) and IL-2cx-treated (red line) 
mice, and the fluorescence minus one (FMO) control (grey shaded area). (C) IL-2R subunit 
abundance on the surface of DC precursors in bone marrow. MDP, monocyte/DC 
progenitor; CDP, common DC progenitor; pre-cDC1, precursor cDC1; pre-cDC2, 
precursor cDC2. Shown are representative histograms from n = 9 mice and N = 3 
independent experiments showing the intensity of IL-2R subunit staining (red line) and 
FMO control (grey shaded area). (D) Phosphorylation of signal transducer and activator of 
transcription (STAT) 5 in mouse cDCs (red line) and Treg cells (black line) upon 
incubation with titrated concentrations of IL-2 (upper panel) or mouse CSF2 (mCSF2; 
lower panel). Data are presented as mean +/- SD (n = 2) from one of 3 independent 
experiments. (E) IL-2R subunit abundance on human CD11c+ HLA-DR+ cDCs compared 
to the abundance on CD4+ T cells. Shown are representative histograms from 6 individual 
donors and N = 3 independent experiments of the respective intensity of IL-2R subunit 
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staining (red line) and FMO control (grey shaded area). (F) Evaluation of cytokine 
signaling by measurement of phosphorylated STAT5 (pSTAT5) in human cDCs and CD4+ 
T cells after incubation with either IL-2 (red line, 1,000 IU/ml) or human CSF2 (hCSF2, 
blue line, 200 ng/ml). Shown are representative histograms from 6 individual donors and 
N = 3 independent experiments of the respective intensity of pSTAT5 staining and FMO 
control (grey shaded area). (G) Lethally-irradiated Il2rg–/– mice reconstituted with a 1:1-
mix of CD45.1+ WT and CD45.2+ Il2rg–/– bone marrow cells receiving indicated treatments 
two months after reconstitution. Data are presented as mean +/- SEM (n = 5 to 9 mice per 
group from N = 3 independent experiments). BM, bone marrow. P-values were calculated 
































































































































































































































































































































































































































































































































Fig. 4. IL-2 immunotherapy induces production of several DC mitogens. 
(A to C) Total splenic cDC counts from Flt3l–/– (n = 9 to 11 mice from N = 4 independent 
experiments) (A), Csf2–/– (n = 4 to 6 mice from N = 2 independent experiments) (B), or 
Flt3l–/– Csf2–/– (n = 20 mice per group from N = 5 independent experiments) (C) mice 
treated with IL-2cx. Data are presented as mean +/- SEM. (D) Proliferation of cDCs in 
Flt3l–/– Csf2–/– mice shown by BrdU incorporation over 3 days. Data are presented as mean 
+/- SEM (n = 14 mice from N = 3 independent experiments). Line indicates region 
quantified. (E and F) Total splenic cDC counts in Flt3l–/– Csf2–/– (n = 5 to 6 mice per group 
from N = 3 independent experiments) (E) or WT (n = 9 mice per group from N = 3 
independent experiments) (F) mice receiving indicated treatments. Data are presented as 
mean +/- SEM. (G) Expansion of WT and Tnfrsf1a/b–/– cDCs following IL-2cx treatment 
of mice previously irradiated lethally and reconstituted with a 1:1-mix of bone marrow 
cells from the indicated donor mice. Data are presented as mean +/- SEM (n = 12 mice per 
group from N = 4 independent experiments). (H) Measurement of mouse FLT3L, CSF2, 
and TNF in serum using enzyme-linked immunosorbent assay (ELISA). Data are presented 
as mean +/- SEM (n = 6 to 11 mice per group from N = 3 independent experiments). (I) 
Measurements of human FLT3L and TNF using proximity extension assay and CSF2 using 
ELISA in sera of patients before and after receiving aldesleukin as described in Fig. 1F (n 
= 10 to 12 individual patients). P-values were calculated using Mann-Whitney test (A), 
unpaired t-tests (B, C, G and H), repeated measure one-way ANOVA with Holm-Sidak 
correction for multiple comparison (E), mixed-effects model with Holm-Sidak correction 
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Fig. 5. IL-2–stimulated innate and adaptive lymphoid cells produce DC-active 
cytokines. 
(A) Mice with chimeric bone marrow (BM) were generated by adoptive transfer (AT) of 
either Il2rg–/–, CD45.1 wild-type (WT), or CD45.2 WT lineage-depleted BM cells into 
lethally-irradiated Il2rg–/– or CD45.1 hosts. Two months later mice were treated as 
indicated. Data are presented as mean +/- SEM (n = 4 to 11 mice per group from N = 2 to 
4 independent experiments). (B) Ki67+ proliferating splenic innate lymphoid cells (ILC, 
left panel) and total ILC counts (right panel) upon IL-2cx treatment. ILCs were defined as 
Lin (CD3, CD5, CD8, CD11b, CD11c, CD19, B220, Ter119)– CD127+ CD90+; with ILC1 
defined as TBET+, ILC2 as GATA3+, and ILC3 as RORγt+ (fig. S5E). Data are presented 
as mean +/- SEM (n = 8 to 14 mice per group from N = 3 to 5 independent experiments). 
(C) Expansion of splenic cDCs in Tcrbd–/– mice after treatment with IL-2cx. Data are 
presented as mean +/- SEM (n = 10 to 13 mice per group from N = 4 independent 
experiments). (D) Expansion of splenic cDCs upon IL-2cx treatment in Rag–/– mice 
additionally depleted of NK cells, ILCs, or both. NK cells were depleted by injection of 
anti-NK1.1 monoclonal antibody; ILCs were depleted by injection of anti-CD90.2 
monoclonal antibody. Data are presented as mean +/- SEM (n = 6 to 9 mice per group from 
N = 3 to 4 independent experiments). (E to G) Diagram of experimental setup: ILC 
precursors or control common lymphoid progenitor (CLP) cells were purified with 
fluorescence-activated cell sorting (FACS) before adoptive transfer into sublethally-
irradiated Il2rg–/– or Il2rg–/– Rag2–/– recipient mice (E). Two months later, immune cell 
populations reconstituted from ILC precursors (AT ILC, upper panel) and CLP (AT CLP, 
lower panel) were analyzed to verify successful engraftment (F). Mice reconstituted with 
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ILC precursors were subsequently treated as indicated and splenic cDCs were quantified 
(G). Data are presented as mean +/- SEM (n = 6 to 7 mice per group from N = 3 independent 
experiments). (H) Flow cytometry-based RNA assay showing expression of Flt3l, Csf2, 
and Tnf mRNA geometric mean-fluorescence intensity (gMFI) in CD4+ regulatory T 
(Treg), CD4+ conventional T (Tcon), CD8+ T, natural killer (NK) cells, ILC1, ILC2, and 
ILC3. Data are presented as mean +/- SEM (n = 6 mice per group from N = 2 independent 
experiments). (I and J) Counts of indicated immune cell subsets producing CSF2 (upper 
graphs) or TNF (lower graphs) in mice treated with IL-2cx or left untreated (n = 8 to 10 
mice per group from N = 2 to 3 independent experiments) (I), and ILCs (n = 6 mice per 
group from N = 3 independent experiments) (J). Data are presented as mean values +/- 
SEM. Statistical significance was tested with Mann-Whitney test (A), multiple t-tests (B, 
H, and I), unpaired t-test (C, G, and J), or one-way ANOVA with Holm-Sidak correction 
for multiple comparison (D). 
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Fig. 6. IL-2 immunotherapy-activated cDCs facilitate anti-tumor responses in mouse 
and human. 
(A) Abundance of CD40, CD80, CD86, MHC-I, and MHC-II on splenic cDCs of untreated 
and IL-2cx-treated mice displayed as representative histograms (left panel) and fold change 
of gMFI normalized to untreated (right panel). Data are presented as mean +/- SEM (n = 9 
mice per group from N = 4 independent experiments). (B) Measurement of antigen uptake 
and processing by cDCs isolated from untreated and IL-2cx-treated mice after 6, 24, 48, 
and 72 hours. Data are presented as mean +/- SEM (n = 9 mice per group from N = 5 
independent experiments). (C) Diagram of experimental setup (left): Ovalbumin peptide-
loaded, purified cDCs were injected into the footpad of naïve mice; after 24 hours, CFSE-
labeled OT-1 cells were adoptively transferred. Two to 3 days later, popliteal lymph nodes 
were removed and OT-1 cell proliferation was quantified (right panel). Data are presented 
as mean +/- SEM (n = 11 to 12 mice per group from N = 5 independent experiments). (D) 
Tumor growth kinetics (left) and quantification of tumor-infiltrating cDCs (day 11) (middle 
and right) in B16-F10 melanoma-bearing mice treated with IL-2cx or anti-PD-1, or left 
untreated. Treatment was initiated when tumors were visible and palpable and applied 
every other day (see also fig. S6B, upper panel). Data are presented as mean +/- SEM (n = 
9 mice per group from N = 3 independent experiments. For tumor volume data, P-value for 
IL-2cx compared to untreated is indicated. (E) Correlation of cDC1 and cDC2 with tumor 
volume of tumor-bearing mice on day 11 from same samples as in (D). (F) Diagram of 
experimental paradigm (left). (Right) Quantification of tumor-infiltrating cDCs in BrafCA 
PtenloxP Tyr::CreERT2 mice harboring 4-hydroxytamoxifen-induced tumors. Treatment 
was started once tumors were visible and palpable. Data are presented as mean +/- SEM (n 
 57 
= 12 to 14 mice per group from N = 2 to 3 independent experiments). (G and H) Tumor 
growth kinetics in Cd11c-DTR (n = 9 to 10 mice per group from 3 independent 
experiments) (G) and Zbtb46-DTR (n = 9 to 10 mice per group from 3 independent 
experiments) (H) BM chimeric mice harboring B16-F10 melanoma. Treatment with IL-
2cx and anti-PD-1 was initiated 4 days after tumor cell injection when tumors were visible 
and palpable and applied 3× weekly for the duration of the experiment. To deplete DCs, 
diphtheria toxin (DT) was applied 3× weekly starting 1 day before tumor inoculation and 
for the duration of the experiment (see also fig. S6B, lower panel). Data are presented as 
mean +/- SEM. (I) Survival analysis of patients with cutaneous melanoma according to IL-
2 signature and BATF3 expression (cut-off at 50%). (J to L) Correlation of BATF3 with 
IL-2 signature (J), with CD4 and CD8B expression, with NK cell signature (K), and with 
FLT3LG-CSF2-TNF expression signature (L). Data were retrieved from TCGA (n = 473 
individual patients). Statistical significance was tested with Mann-Whitney test (A), two-
way ANOVA with Holm-Sidak correction for multiple comparison (B and D, left panel), 
unpaired t-test (C), one-way ANOVA with Holm-Sidak correction for multiple comparison 
(D, middle graph cDC1), Kruskall-Wallis test with Dunn’s multiple comparison test (D, 
right graph cDC2, and F), Pearson correlation coefficients (E, and J to L), Mixed-effects 
model with Holm-Sidak correction for multiple comparison (G to H), and Logrank test (I). 
